Category DPP-IV

Zero DLTs were reported during dosage verification

Zero DLTs were reported during dosage verification. had been treated with tislelizumab 200?mg once every 3 intravenously?weeks (Q3W). Median duration of follow-up Solifenacin succinate was 8.1 months (range 0.2C21.9). No DLTs had been reported through the stage 1 dose-verification research…